The purpose of this shared resource is to provide human tissues, biological fluids, and expert pathologic interpretation for investigators in all of the projects under the direction of expert pathologists. The Histopathology and Tissue/Biologic Fluids Resource has been in existence since 1986 and expanded under the support of the GI SPORE. As of this year, the Resource includes 1698 banked colorectal carcinoma resection specimens, 354 colorectal adenoma samples, 325 hepatic metastases of colorectal carcinoma, 1013 pancreatic carcinoma specimens, 588 xenografts of colorectal carcinoma, 101 pancreatic carcinoma xenografts, 5298 blood specimens from individuals at risk for colorectal carcinoma, and 867 blood specimens from patients with pancreatic carcinoma. Formalin-fixed paraffin-embedded tissues, frozen materials and clinical and outcome data are available for the vast majority of resection specimens. Most recently, this resource has expanded its collections to include high quality snap frozen and formalin fixed samples of end stage pancreatic or colorectal cancer from 120 rapid autopsy participants. 133 tissue microarrays of colorectal and pancreatic neoplasms and diseases have been created. Eight fully characterized pancreatic carcinoma cell lines have been prepared from human tumors and shared with the ATCC. The biospecimens are harvested and banked in accordance with the National Cancer Institute's Best Practice Guidelines for Biorepositories. Distribution of these specimens to SPORE investigators has resulted in over 100 publications. This Core procures additional xenografts, fresh frozen colorectal and pancreatic neoplasms and blood and pancreatic juice samples, and provides expert pathologic consultation to investigators. Specimens are collected under the supervision of pathologists with expertise in colorectal and pancreatic neoplasia in close collaboration with clinical specialists in these areas and in similarly close collaboration with basic research investigators to maximize translational impact of the projects. Clinical and family histories are entered into a password protected web-based tracking system for our pancreatic cases. This Web-based interface follows the recommendations of the National Research Council, and includes user authentication, encryption, audit trails, and disaster recovery. A mechanism is in place for prioritization of distribution of requested resources to investigators within and external to the Johns Hopkins GI Cancer SPORE. Biosamples have been shared with investigators at over 50 other institutions. Collaboration with investigators at other centers fosters the accrual of rare tumor types.
Neoplasms of the pancreas and colon are among the most common causes of cancer related death in the United States. This core resource will thus support the projects of this application related to the diagnosis and treatment of pancreatic and/or colorectal neoplasia with high quality tissues and biosamples.
|Hata, Tatsuo; Dal Molin, Marco; Suenaga, Masaya et al. (2016) Cyst Fluid Telomerase Activity Predicts the Histologic Grade of Cystic Neoplasms of the Pancreas. Clin Cancer Res 22:5141-5151|
|Childs, Erica J; Chaffee, Kari G; Gallinger, Steven et al. (2016) Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. Cancer Epidemiol Biomarkers Prev 25:1185-91|
|Yachida, Shinichi; Wood, Laura D; Suzuki, Masami et al. (2016) Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma. Cancer Cell 29:229-40|
|Rucki, Agnieszka A; Foley, Kelly; Zhang, Pingbo et al. (2016) Heterogeneous stromal signaling within the tumor microenvironment controls the metastasis of pancreatic cancer. Cancer Res :|
|Faisal, Farzana; Tsai, Hua-Ling; Blackford, Amanda et al. (2016) Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. Am J Clin Oncol 39:18-26|
|Kumar, Abhijeet; Le, Dung T (2016) Hepatocellular Carcinoma Regression After Cessation of Immunosuppressive Therapy. J Clin Oncol 34:e90-2|
|Poruk, Katherine E; Blackford, Amanda L; Weiss, Matthew J et al. (2016) Circulating Tumor Cells Expressing Markers of Tumor Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma. Clin Cancer Res :|
|Masica, David L; Dal Molin, Marco; Wolfgang, Christopher L et al. (2016) A novel approach for selecting combination clinical markers of pathology applied to a large retrospective cohort of surgically resected pancreatic cysts. J Am Med Inform Assoc :|
|Poruk, Katherine E; Valero 3rd, Vicente; Saunders, Tyler et al. (2016) Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Ann Surg 264:1073-1081|
|Foley, Kelly; Kim, Victoria; Jaffee, Elizabeth et al. (2016) Current progress in immunotherapy for pancreatic cancer. Cancer Lett 381:244-51|
Showing the most recent 10 out of 795 publications